The recent announcement from researchers at Aalto University in Finland marks a significant advancement in the fight against dry age-related macular degeneration. This innovative laser heat treatment uses carefully controlled near-infrared light to gently warm retinal tissue, activating the eye's natural protective and repair mechanisms without causing damage. Early laboratory and animal studies suggest it could slow or even halt disease progression when applied in the initial stages.
Dry age-related macular degeneration, often called dry AMD, affects millions worldwide and remains one of the leading causes of vision loss in older adults. Unlike the wet form, which involves abnormal blood vessel growth treatable with injections, dry AMD has historically lacked effective interventions beyond lifestyle measures such as nutrition and smoking cessation.
Understanding Dry Age-Related Macular Degeneration
Dry AMD develops when the retinal pigment epithelium, a layer of cells supporting the light-sensitive photoreceptors in the macula, begins to deteriorate. This leads to the accumulation of drusen, yellow deposits beneath the retina, and gradual thinning of the macular tissue. Over time, central vision blurs, making tasks like reading, driving, and recognizing faces increasingly difficult. The condition typically progresses slowly but can advance to geographic atrophy in later stages, resulting in permanent central vision loss.
Key risk factors include advancing age, genetics, smoking, obesity, and prolonged exposure to ultraviolet light. Global prevalence continues to rise with aging populations, underscoring the urgent need for new therapeutic approaches that go beyond symptom management.
Current Treatment Landscape and Gaps
Existing options for dry AMD focus primarily on slowing progression through antioxidant supplements like the AREDS2 formula and lifestyle modifications. Anti-VEGF therapies revolutionized care for wet AMD but offer no benefit for the dry form. Earlier laser techniques, such as photocoagulation, carried risks of scarring and were largely abandoned for dry AMD due to limited efficacy and potential harm.
The absence of disease-modifying treatments has left patients and clinicians with few proactive tools. This gap has driven extensive research into light-based and thermal therapies that stimulate cellular resilience rather than destroy tissue.
The Aalto University Breakthrough: Research Details
Published in Nature Communications in late 2025, the study led by Professor Ari Koskelainen details a novel method of laser-induced thermal stimulation. The approach differs from traditional photobiomodulation by emphasizing precise, monitored heating to trigger hormetic responses—beneficial adaptations to mild stress—in retinal cells.
The research team developed technology allowing simultaneous heating with near-infrared laser light and real-time temperature feedback. This ensures the retinal pigment epithelium reaches therapeutic temperatures of a few degrees above normal while staying well below the 45°C threshold that risks cellular damage.
Preclinical work in mouse models of AMD and pig eyes demonstrated reduced thickness in Bruch's membrane, enhanced autophagy (cellular cleanup), and upregulation of heat shock proteins that protect against oxidative stress. These changes correlated with preserved retinal structure and function over time.
Photo by Opt Lasers on Unsplash
How the Laser Heat Treatment Works Step by Step
The procedure begins with a comprehensive eye examination and imaging to confirm suitability and map the treatment area. A specialized delivery system then applies short bursts of near-infrared laser light to the retina through the pupil.
During application, integrated sensors monitor tissue temperature continuously, adjusting energy output to maintain the optimal mild heating range. This controlled warmth activates protective pathways, including the production of proteins that help clear cellular debris and bolster mitochondrial function in retinal cells.
Sessions are brief and non-invasive, requiring no anesthesia or recovery downtime. The goal is periodic treatments during early or intermediate stages to reinforce the retina's natural defenses before significant vision loss occurs.
Preclinical Evidence and Promising Outcomes
In animal models, the thermal stimulation consistently reduced signs of retinal stress and slowed degenerative changes associated with dry AMD. Pig studies provided critical safety data, confirming no histological damage even after repeated applications when temperature control was maintained.
These findings represent the first evidence that a heat-based intervention can meaningfully engage the eye's self-repair systems in a targeted, non-destructive manner. Researchers observed improvements in cellular metabolism and reduced inflammation markers, pointing toward disease modification rather than mere symptom relief.
Transition to Human Clinical Trials
Following successful preclinical validation, the team established the Maculaser startup to advance commercialization. Patient trials are scheduled to begin in Finland during spring 2026, focusing initially on individuals with early-stage dry AMD.
The trial design emphasizes safety, optimal dosing, and measurable outcomes such as changes in visual acuity, contrast sensitivity, and retinal imaging biomarkers. If results mirror animal data, regulatory pathways could lead to availability within three years, offering a new option for patients currently underserved by existing therapies.
Implications for Patients, Clinicians, and Research Communities
For individuals living with dry AMD, this development signals hope for proactive intervention that preserves independence and quality of life. Early detection through routine screenings becomes even more valuable if treatment can be initiated before symptoms intensify.
Ophthalmologists may soon incorporate thermal dosimetry-guided laser sessions into comprehensive care plans, complementing nutritional counseling and monitoring. The approach also highlights the value of interdisciplinary collaboration between biomedical engineers, cell biologists, and clinicians.
Broader academic communities benefit from the demonstration that precise thermal control can unlock hormetic benefits in delicate tissues, potentially informing treatments for other degenerative conditions.
Photo by LaserWorld LaserBeam on Unsplash
Future Outlook, Challenges, and Opportunities
While excitement is warranted, challenges remain. Large-scale human trials must confirm long-term safety and efficacy across diverse populations. Manufacturing scalable, affordable devices and training specialists will be essential for widespread adoption.
Integration with existing diagnostic tools, such as optical coherence tomography, could enable personalized treatment plans. Ongoing research may refine wavelengths, pulse patterns, and combination therapies to maximize benefits.
This breakthrough underscores the accelerating pace of innovation in ophthalmology, where academic research directly translates into clinical potential. It also opens avenues for exploring similar thermal or light-based strategies in related retinal diseases.
Actionable Insights for Stakeholders
Patients concerned about dry AMD should consult retina specialists about current monitoring protocols and emerging options. Staying informed through reputable sources empowers informed discussions during appointments.
Researchers and institutions can explore partnerships or funding opportunities in translational eye research. Academic programs emphasizing biomedical engineering and vision science stand to play pivotal roles in refining these technologies.
Healthcare systems may consider incorporating early AMD screening into senior wellness initiatives to identify candidates for future interventions promptly.